Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Fierce Pharma
NOVEMBER 28, 2022
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy. ntaylor. Mon, 11/28/2022 - 10:11.
Fierce Pharma
NOVEMBER 28, 2022
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy. ntaylor. Mon, 11/28/2022 - 10:11.
MedCity News
DECEMBER 1, 2022
Thanks to the convergence of cloud technologies, AI, and refined lung data, we are in a new era for those with chronic lung disease. In this new world, lung intelligence provides fast, precision measures of treatment efficacy so new drugs can blaze through the trial pipeline.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 29, 2022
The National Health Service (NHS) in England, UK, has expedited the rollout of Bayer ’s new life-extending drug, darolutamide, to treat the most advanced kinds of prostate cancer that have spread to other body parts. With the latest development, NHS will become the first healthcare system in Europe to offer this drug to prostate cancer patients. Nearly 9,000 men with prostate cancer will be eligible to receive this treatment.
PharmaVoice
NOVEMBER 28, 2022
After nearly five years, the homicide case involving pharma billionaires continues to perplex investigators.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Fierce Pharma
DECEMBER 2, 2022
With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker. fkansteiner. Fri, 12/02/2022 - 09:51.
MedCity News
DECEMBER 2, 2022
From streamlining long-held manual processes to creating entirely new diagnostic devices, new tech is cropping up all over the medtech industry—resulting in a real-world impact on patients’ quality of life.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
DECEMBER 1, 2022
Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials. A 2018 NIH survey found that patients felt clinical trial participation to be inconvenient and burdensome, and nearly half (49.0%) said it disrupted their daily routine. In 2021, a CISCRIP Perceptions and Insights Study reported more disruption to daily routines compared to previous years, citing length of visits, travel, and diagnostic tests as top burdens
Fierce Pharma
DECEMBER 1, 2022
Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug. aliu. Thu, 12/01/2022 - 15:03.
MedCity News
DECEMBER 2, 2022
Health system leaders believe that improving patient access should be their top priority when strategically planning for 2023, according to a new report from the KLAS Research and UPMC’s Center for Connected Medicine. To improve patient access, respondents agreed that their health systems will need to make changes in three key areas — people, process and technology.
Pharmaceutical Technology
NOVEMBER 29, 2022
For several decades, researchers have been investigating the role of ketamine in treating depression. Now, efforts are underway to study ketamine’s effects in Parkinson’s disease, fibromyalgia, and Rett syndrome. On November 14, the Canadian developer PharmaTher announced positive data from a Phase I/II study where ketamine was used to treat levodopa-induced dyskinesia in Parkinson’s disease.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
NOVEMBER 27, 2022
Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products. Incidents such as the hormone replacement therapy drug shortage in early 2022 have shown the damaging impact supply chain issues can have on people who depend on these drugs.
Fierce Pharma
DECEMBER 1, 2022
With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2. kdunleavy. Thu, 12/01/2022 - 10:14.
MedCity News
DECEMBER 2, 2022
Lumen sells a handheld device that measures users’ metabolism through breath and connects to an app that helps track goals and provides nutrition coaching. The funding round was led by Pitango Venture Capital, and included participation from Hanwha Group and Resolute Ventures.
Pharmaceutical Technology
NOVEMBER 28, 2022
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. Under the agreement, AstraZeneca will be responsible for the development and marketing of oral therapy for inflammatory and respiratory diseases with a key focus on chronic obstructive pulmonary disease (COPD).
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Medgadget
DECEMBER 1, 2022
Bigfoot Biomedical , a medtech company based in California, has developed the Bigfoot Unity System, a diabetes management technology for patients on multiple daily injection therapy. The system uses continuous glucose monitoring data and doctor recommendations to provide insulin dose recommendations, helping patients to avoid uncertainty. The company argues that type 2 diabetes patients have been historically underserved by the medtech industry, in part because such patients typically tend to be
Fierce Pharma
DECEMBER 1, 2022
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial. ntaylor. Thu, 12/01/2022 - 09:45.
MedCity News
DECEMBER 1, 2022
An AHIP survey found that 73% of commercially-insured telehealth users think that Congress should make telehealth provisions permanent. These provisions were put in place to meet Americans’ needs during Covid-19.
PharmaTech
DECEMBER 2, 2022
QMM is an evolutionary advancement in FDA’s quality management maturity initiative that provides industry with a viable methodology to assess and improve manufacturing quality and supply chain reliability.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Medico Reach
DECEMBER 2, 2022
To bring effective medicines and Innovations in healthcare industry , a Clinical Research Organization or Contract Research Organization (CRO) are a must for the Biotech, Medtech, and pharma industries. A CRO offers comprehensive support to their efforts to test, examine, refine and market the latest medicines and devices that help in improving Healthcare Industry.
Fierce Pharma
NOVEMBER 30, 2022
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent. zbecker. Wed, 11/30/2022 - 10:55.
MedCity News
NOVEMBER 29, 2022
As gene sequencing, machine learning, powerful imaging, sensors, gene and cell therapies make their way out of academic labs into everyday healthcare, our approach to healthcare is changing. For the first time, not only can we pinpoint the molecular and genetic causes of disease, but we also have the technologies to access them. On the back of this, prevention and cures are becoming possible.
Celeritas
NOVEMBER 30, 2022
In America, the percentage of households that own or adopt animals is rising every year. A survey conducted by the APPA in 2021-22 showed that 70% of households owned a pet. Additionally, as knowledge of potential threats spreads, veterinary appointments are now part of a pet owner’s routine. The demand for and willingness to spend on extensive care, pet health plans, etc. are also on the rise.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Pharmaceutical Technology
NOVEMBER 30, 2022
Multiple sclerosis (MS) is an autoimmune disease causing chronic inflammation and demyelination of the nerves, affecting around 2.5 million people worldwide. While patients diagnosed with relapsing MS (RMS) have a wide range of marketed treatment options, patients diagnosed with progressive MS, especially primary progressive MS (PPMS), have very limited treatment options.
Fierce Pharma
DECEMBER 2, 2022
UPDATED: GSK, with new trial win, looks to expand PD-1 Jemperli in endometrial cancer. zbecker. Fri, 12/02/2022 - 11:22.
MedCity News
NOVEMBER 29, 2022
Nvidia unveiled new tools designed to make it easier for hospitals to integrate AI models related to medical imaging into their clinical workflows. The tools have been adopted by major cloud infrastructure providers, as well as healthcare providers and AI software companies. Some of these include Cincinnati Children’s Hospital, University of California San Francisco, England’s National Health Service and Qure.ai.
PM360
NOVEMBER 29, 2022
When developing content for new drug labels, life sciences companies’ regulatory teams face challenges in gathering intelligence to better understand competitive factors, market dynamics, and effective approval strategies. To overcome these barriers, organizations are increasingly looking to technology such as natural language processing (NLP) to reduce the manual, repetitive steps of acquiring regulatory intelligence.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Legacy MEDSearch
NOVEMBER 29, 2022
Densitas ® Inc., a global provider of A.I. solutions for digital mammography and breast screening announced that Desert Imaging has implemented the densitas® IntelliMammo platform across their health system. The adoption of intelliMammo reinforces Desert Imaging’s established commitment to maintaining robust organization-wide quality improvement initiatives.
Fierce Pharma
NOVEMBER 30, 2022
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance. aliu. Wed, 11/30/2022 - 16:32.
MedCity News
NOVEMBER 29, 2022
We now see the next wave of potential cancer therapies on the horizon, propelled by significant advancements in immunology, as well as an increased understanding of tumor-driven mechanisms of immune evasion.
PM360
NOVEMBER 29, 2022
The White House’s recent Health Sector Climate Pledge brought together hospitals and healthcare companies that committed to reduce greenhouse gas emissions 50% by 2030. It is a long overdue effort to promote sustainability and combat climate change. The social, economic, and environmental impact of such initiatives are clear, but only a few companies in the healthcare industry have made this kind of commitment so far.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Let's personalize your content